359 related articles for article (PubMed ID: 16896314)
21. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
Kovacs GG; Milenkovic IJ; Preusser M; Budka H
Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
[TBL] [Abstract][Full Text] [Related]
22. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
24. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.
Kress GJ; Reynolds IJ
Neurobiol Dis; 2005 Dec; 20(3):639-45. PubMed ID: 15996475
[TBL] [Abstract][Full Text] [Related]
25. Progressive dopaminergic neurodegeneration of substantia nigra in the zitter mutant rat.
Nakadate K; Noda T; Sakakibara S; Kumamoto K; Matsuura T; Joyce JN; Ueda S
Acta Neuropathol; 2006 Jul; 112(1):64-73. PubMed ID: 16609850
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
[TBL] [Abstract][Full Text] [Related]
27. [Incidental occurrence of Lewy bodies in the brains of elderly patients--the relevance to aging and Parkinson's disease].
Wakabayashi K; Takahashi H; Oyanagi K; Ikuta F
No To Shinkei; 1993 Nov; 45(11):1033-8. PubMed ID: 8135950
[TBL] [Abstract][Full Text] [Related]
28. The intrastriatal injection of thrombin in rat induced a retrograde apoptotic degeneration of nigral dopaminergic neurons through synaptic elimination.
Herrera AJ; de Pablos RM; Carreño-Müller E; Villarán RF; Venero JL; Tomás-Camardiel M; Cano J; Machado A
J Neurochem; 2008 May; 105(3):750-62. PubMed ID: 18179476
[TBL] [Abstract][Full Text] [Related]
29. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra.
Nosheny RL; Bachis A; Aden SA; De Bernardi MA; Mocchetti I
J Neurobiol; 2006 Oct; 66(12):1311-21. PubMed ID: 16967504
[TBL] [Abstract][Full Text] [Related]
30. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
31. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.
Chan-Palay V; Asan E
J Comp Neurol; 1989 Sep; 287(3):373-92. PubMed ID: 2570794
[TBL] [Abstract][Full Text] [Related]
32. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
Korecka JA; Eggers R; Swaab DF; Bossers K; Verhaagen J
Restor Neurol Neurosci; 2013; 31(2):155-67. PubMed ID: 23271419
[TBL] [Abstract][Full Text] [Related]
33. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].
Wakabayashi K
Rinsho Shinkeigaku; 2008 Nov; 48(11):981-3. PubMed ID: 19198138
[TBL] [Abstract][Full Text] [Related]
34. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
35. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
Sedaghat K; Finkelstein DI; Gundlach AL
Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
[TBL] [Abstract][Full Text] [Related]
36. Dual immunofluorescence study of citrullinated proteins in Parkinson diseased substantia nigra.
Nicholas AP
Neurosci Lett; 2011 May; 495(1):26-9. PubMed ID: 21414385
[TBL] [Abstract][Full Text] [Related]
37. An altered histaminergic innervation of the substantia nigra in Parkinson's disease.
Anichtchik OV; Rinne JO; Kalimo H; Panula P
Exp Neurol; 2000 May; 163(1):20-30. PubMed ID: 10785440
[TBL] [Abstract][Full Text] [Related]
38. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
39. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
[TBL] [Abstract][Full Text] [Related]
40. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein.
Lee HJ; Khoshaghideh F; Lee S; Lee SJ
Eur J Neurosci; 2006 Dec; 24(11):3153-62. PubMed ID: 17156376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
